When the Cincinnati pharmaceutical firm William S. Merrell submitted an application to the Food and Drug Administration in late 1960, executives anticipated a swift approval for a new German-made sedative. They hoped the drug, thalidomide, would be on American store shelves by Christmas. That approval never came—not that year, and not the next. A determined FDA medical reviewer, Dr. Frances Oldham Kelsey, repeatedly refused to greenlight the drug for general use, citing insufficient safety data. Her skepticism ultimately shielded the United States from the full-scale catastrophe that unfolded in Europe, where thalidomide was widely prescribed and caused thousands of severe birth defects.
Dr. Kelsey's vigilance became the stuff of legend. President John F. Kennedy publicly honored her for sparing the nation "this terrible human tragedy which has been visited on families in Germany." Her actions fundamentally reshaped how the FDA evaluates and approves drugs, ushering in an era of stricter clinical testing and regulatory oversight that persists today. Yet the narrative of America's narrow escape from thalidomide's horrors is not entirely accurate.
The truth is more complicated and, for some families, far more painful. Even without formal FDA approval for general use, doctors across the United States were already distributing thalidomide to thousands of patients as part of clinical trials and investigational programs. Pregnant women were among those who received the drug, often without being told they were taking an experimental medication. As a result, some American children were born with the same devastating limb deformities seen in Europe.
Those children are now adults in their sixties, and they are demanding that the federal government formally recognize their existence. For decades, their stories have been overshadowed by the triumphant tale of Kelsey's blockade. Many doctors today insist that thalidomide never harmed Americans, a claim that survivors find deeply frustrating. "We go to doctors today who say it didn't happen here in the United States. Oh yeah, it did," said Gwen Riechmann, who was born with phocomelia, the signature condition caused by thalidomide in which limbs are severely shortened or absent.
Riechmann's experience is a case in point. In the early 1960s, when her mother was pregnant with her, a doctor handed her a new sedative to help her sleep. That sedative was thalidomide, provided through a loosely regulated distribution channel that bypassed the FDA's formal approval process. Riechmann's mother was never informed she was part of an experiment, nor was she warned of the drug's potential dangers. The result was a lifelong disability that Riechmann and other survivors say the U.S. government has long refused to acknowledge.
Phocomelia itself is rare, but it occurs slightly more frequently outside the United States—particularly in Britain and Germany, where thalidomide was sold openly under brand names like Contergan and Distaval. In those countries, the scale of the tragedy was undeniable, leading to widespread public outcry, changes in drug laws, and compensation programs for survivors. In the U.S., however, the prevailing narrative of Kelsey's successful intervention has made it difficult for homegrown survivors to gain visibility or support. Their numbers are unknown, but advocates argue they are far higher than official estimates suggest.
The discrepancy stems from how thalidomide was tested in America. Pharmaceutical companies distributed the drug to thousands of physicians, who in turn gave it to patients—including pregnant women—under the guise of clinical investigation. These trials were not tightly controlled, and record-keeping was often poor. When thalidomide's link to birth defects became undeniable in 1961, the drug was pulled from the market, but by then many women had already been exposed. The FDA's insistence that the drug was never approved for general use has allowed the government to sidestep responsibility for those who were harmed.
Survivors and their allies argue that this technicality has been used to deny them recognition, medical assistance, and compensation. Many have spent years seeking acknowledgment from federal agencies, only to be told that thalidomide was never legally marketed in the U.S. That argument ignores the reality that the drug was widely available through investigational channels. "The government admits that thalidomide caused birth defects, but they won't admit that it happened here," said one advocate familiar with the survivors' campaign. "It's a distinction without a difference for the people who are living with the consequences."
The fight for recognition echoes broader debates about pharmaceutical accountability and the rights of patients harmed by experimental treatments. It also highlights the legacy of a regulatory system that, while strengthened by Kelsey's actions, still left gaps through which dangerous drugs could reach vulnerable populations. For survivors like Riechmann, the issue is not just historical accuracy—it is about identity and justice. They want the federal government to formally acknowledge that American children were born with thalidomide-related disabilities and to provide the support that has long been denied.
As they age, these survivors face mounting health challenges, including mobility issues and chronic pain related to their deformities. Without official recognition, many struggle to access specialized care or disability benefits tailored to their condition. Their campaign is not merely a quest for a symbolic apology; it is a practical plea for resources and understanding. They argue that the U.S. government's refusal to count them is a form of erasure that compounds the original harm.
The story of thalidomide in America is thus a tale of two narratives: one of regulatory triumph, the other of hidden suffering. Dr. Kelsey deserves her place in history for preventing a wider disaster, but her success has inadvertently obscured the experiences of those who slipped through the cracks. As Gwen Riechmann and others like her continue to speak out, they are challenging the nation to confront a uncomfortable truth: that the tragedy they call "foreign" happened here too, and its survivors are still waiting to be seen.
(0)